Brucellosis Market Share
Traditional vaccines, such as RB51 and S19 for cattle, have proven effective in reducing Brucella infections. Newer vaccine research focuses on developing safer and more effective options for sheep, goats, and other animals. Companies are investing in biotechnological innovations to enhance immune responses, reduce side effects, and extend vaccine coverage.
Public-private partnerships are critical in the market. Governments fund vaccination campaigns, while private companies provide technological and logistical support. These initiatives help combat outbreaks and strengthen national animal health programs. Vaccination, combined with diagnostics and surveillance, forms a multi-pronged strategy to control brucellosis.
Economic impact is a significant factor driving vaccine adoption. Brucellosis in livestock leads to reproductive failures, lower milk production, and high culling rates. By preventing infections, vaccines protect farmers’ livelihoods and contribute to regional food security.
Global market players such as Hester Biosciences Limited, Merck Animal Health, and Zoetis are expanding their product portfolios and entering emerging markets to address unmet needs. The Brucellosis Market is expected to continue growing, supported by increasing awareness, technological advancements, and government programs.
For detailed insights, refer to the Brucellosis Market report.